EGFR-STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1-positive prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Prostate cancer (PCa) is a leading cause of cancer death, with limited targeted treatment options.
• Genomic rearrangements of ETS transcription factors (ERG, ETV1) are common in PCa, but their clinical significance is unclear.
• Understanding molecular drivers is crucial for developing effective PCa therapies.

Purpose of the Study:

• To investigate the functional role of ETV1 in prostate cancer pathogenesis.
• To identify downstream signaling pathways regulated by ETV1.
• To explore novel therapeutic strategies targeting ETV1-driven PCa.

Main Methods:

• Utilized prostate cancer cell lines with ETV1 or ERG overexpression.
• Performed gene expression and signaling pathway analysis.
• Validated findings using external patient datasets and ChIP-seq.
• Tested combined inhibition of EGFR and STAT3 in vitro.

Main Results:

• Identified a positive feedback loop between ETV1 and EGFR, with STAT3 as a downstream effector.
• Confirmed significant upregulation of EGFR and STAT3 in ETV1-positive PCa.
• Demonstrated that combined EGFR and STAT3 inhibition reduced PCa cell growth.
• ETV1 directly targets EGFR and STAT3.

Conclusions:

• EGFR-STAT3 activation is a novel ETV1-regulated oncogenic pathway in PCa.
• Combined EGFR and STAT3 inhibition represents a potential therapeutic strategy for ETV1-altered prostate carcinomas.
• This approach could benefit the 8-10% of PCa patients with ETV1 rearrangements.